Nancy Kohl, Ph.D., is a consultant to the Institute for Applied Cancer Science at MD Anderson Cancer Center, where she co-leads the SHP2 inhibitor program. She previously served as vice president of biology at Blueprint Medicines, where she led a team of biologists in discovering and developing targeted kinase medicines for patients with genomically defined diseases. Prior to joining Blueprint, Dr. Kohl was a principal research scientist and head of research in the Center for Novel Experimental Therapeutics at Dana-Farber Cancer Institute, where she started a new integrative research center focused on evaluating experimental cancer therapies in relevant in vivo disease models to generate preclinical data to inform efficient clinical trials. Dr. Kohl spent over two decades at Merck Research Laboratories, working initially in the area of anti-viral drug discovery and then in oncology; her efforts contributed to the approval of two drugs and the advancement of numerous compounds into clinical trials. Dr. Kohl is an author of more than 90 peer-reviewed papers in the fields of anti-viral and oncology drug discovery. She holds a Ph.D. degree in biochemistry from Columbia University and completed post-doctoral work at the MIT Center for Cancer Research.